SeaStar Medical Holding Corporation - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ICU Nasdaq 3840 www.seastarmedical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SeaStar Medical Holding Corporation

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial - Jan 22nd, 2025 12:30 pm
SeaStar Medical says FDA approves feasibility study with SCD-ADULT - Jan 14th, 2025 1:35 pm
FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome - Jan 13th, 2025 1:30 pm
SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer - Jan 8th, 2025 1:30 pm
SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial - Dec 23rd, 2024 12:00 pm
SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications - Dec 11th, 2024 11:30 am
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024 - Dec 4th, 2024 1:30 pm
SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial - Dec 3rd, 2024 1:30 pm
SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024 - Nov 26th, 2024 1:00 pm
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares - Nov 22nd, 2024 1:30 pm
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer - Nov 15th, 2024 1:30 pm
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update - Nov 13th, 2024 10:05 pm
FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis - Nov 6th, 2024 2:00 pm
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial - Nov 1st, 2024 12:30 pm
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE - Oct 31st, 2024 12:30 pm
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update - Oct 25th, 2024 3:32 pm
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Oct 25th, 2024 12:30 pm
SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial - Oct 23rd, 2024 12:30 pm
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers - Oct 22nd, 2024 12:30 pm
SeaStar hits halfway mark in AKI trial for selective cytopheretic device - Oct 21st, 2024 3:19 pm